SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- Facebook: The Song — Yes, We're Serious

TOP HEADLINES

» Markets | Economy | Companies

- JPMorgan Trading Loss: Did Regulators Overlook the Risk?

PHARMA'S MARKET VIDEO

» More

Wall Street Protests 29 Apr 2010
Following a big demonstration in favor of financial regulation right outside the NYSE, with CNBC's Mike Huckman.
March on Wall Street 29 Apr 2010
Main Street takes to Wall Street today with thousands of union community activists marching to make the big banks pay, with CNBC's Mike Huckman.
Mike Huckman: Reporter's Reporter 29 Apr 2010
Original air date, June 26, 2002.
SBUX Beats the Street 21 Apr 2010
CNBC's Mike Huckman has Starbucks' earnings breakdown.

The Orange Squeeze on Dimon

16 Apr 2010

Some students at Syracuse University have a different idea rather than having JPMorgan's chairman/CEO Jamie Dimon deliver this year's commencement speech, reports CNBC's Mike Huckman.

Nasdaq Outperforms 14 Apr 2010
The Nasdaq easily outperforming the other major indexes today, with CNBC's Mike Huckman.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

Pharma's Market

Text Size

Nov.24

9:15 AM ET

Monday, 24 Nov 2008

Pharma Updates And What You Need To Know

Posted By:Mike Huckman

Sectors:Health Care Equipment and Services | Health Care | Pharmaceuticals

As the market remains focused on Citi and the President-elect's midday cabinet announcement there are a few newsworthy things going on in biopharmaland.

Johnson & Johnson [JNJ Loading... () ] is buying Omrix Biopharmaceuticals[OMRI Loading... () ] for $438 million in cash. And Bristol-Myers Squibb [BMY Loading... () ] has moved forward on an option to buy into an experimental drug at Exelixis (EXEL), entitling the baby biotech to a $20 million cash payment from BMY.

Genentech [DNA Loading... () ] announced positive results from a big study on Avastin for breast cancer. The biotech giant hopes to use the data to win full out FDA approval of the drug for that type of cancer.

Meantime, mark December 4th on your calendar. Dow component Merck [MRK Loading... () ] announced this morning that's when it will hold a conference call to provide new financial guidance. It's become standard operating procedure for the drugmaker to do that a week ahead of its analyst/investor meeting.

Coincidentally, or maybe not, MRK's cholesterol drug partner Schering-Plough[SGP Loading... () ] is holding its Research and Development Day with Wall Street today. In his opening remarks Chairman and CEO Fred Hassan, among many other things, touched on the economy. "Our sector is more resilient than most, but we're not immune," he said. I'm at the company's HQ in Kenilworth, NJ to do a live interview with Hassan around 1:30 pm ET on "Power Lunch."

Finally, a note about the front-page article about Pfizer's [PFE Loading... () ] Viagra for athletes in "The New York Times" on Sunday. It's a good "talk about" story for the water-cooler, but will have little, if any, material impact on Viagra sales.

Far down in the piece it mentioned side effects including "priapism." But the reporter/editors apparently assumed readers would know what that means. It's the side effect rattled off in impotence drug commercials that often draws chuckles and provides comedians with stand-up routine material about erections lasting four hours or more.